Interestingly, ADCT-301 treatment in preclinical models and in patients with advanced solid tumors or lymphomas resulted in transient reduction of Treg cells, while CD4+ and CD8+ T cells were unaffected, which might enhance ADCT-301-mediated anti-tumor activity55–57. Here, CD4 is linked to neoplasm.